AngioDynamics, Inc. (ANGO)
USD 8.93
(-3.56%)
USD 8.93
(-3.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 112.08 Million USD | -27.38% |
| 2023 | 154.34 Million USD | 20.33% |
| 2022 | 128.26 Million USD | 5.15% |
| 2021 | 121.98 Million USD | -12.65% |
| 2020 | 139.64 Million USD | -36.99% |
| 2019 | 221.62 Million USD | 36.07% |
| 2018 | 162.87 Million USD | -14.69% |
| 2017 | 190.93 Million USD | -13.62% |
| 2016 | 221.03 Million USD | -3.31% |
| 2015 | 228.6 Million USD | -12.84% |
| 2014 | 262.26 Million USD | -1.05% |
| 2013 | 265.05 Million USD | 31.42% |
| 2012 | 201.68 Million USD | 534.27% |
| 2011 | 31.79 Million USD | -2.39% |
| 2010 | 32.57 Million USD | -10.77% |
| 2009 | 36.5 Million USD | -31.16% |
| 2008 | 53.03 Million USD | 12.07% |
| 2007 | 47.32 Million USD | 248.94% |
| 2006 | 13.56 Million USD | 28.4% |
| 2005 | 10.56 Million USD | -15.46% |
| 2004 | 12.49 Million USD | -51.13% |
| 2003 | 25.56 Million USD | 22.09% |
| 2002 | 20.94 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 66.14 Million USD | -57.14% |
| 2024 FY | 112.08 Million USD | -27.38% |
| 2024 Q3 | 106.14 Million USD | 7.87% |
| 2024 Q2 | 98.39 Million USD | 48.76% |
| 2024 Q4 | 112.08 Million USD | 5.6% |
| 2023 Q4 | 154.34 Million USD | 6.3% |
| 2023 Q3 | 145.19 Million USD | -3.36% |
| 2023 Q2 | 150.24 Million USD | 4.62% |
| 2023 Q1 | 143.61 Million USD | 11.97% |
| 2023 FY | 154.34 Million USD | 20.33% |
| 2022 Q1 | 119.81 Million USD | -1.78% |
| 2022 FY | 128.26 Million USD | 5.15% |
| 2022 Q2 | 121.73 Million USD | 1.6% |
| 2022 Q4 | 128.26 Million USD | 13.02% |
| 2022 Q3 | 113.48 Million USD | -6.78% |
| 2021 Q1 | 128.7 Million USD | -7.83% |
| 2021 Q4 | 121.98 Million USD | -4.19% |
| 2021 Q2 | 134.17 Million USD | 4.25% |
| 2021 Q3 | 127.3 Million USD | -5.12% |
| 2021 FY | 121.98 Million USD | -12.65% |
| 2020 FY | 139.64 Million USD | -36.99% |
| 2020 Q2 | 111.06 Million USD | 45.59% |
| 2020 Q3 | 121.48 Million USD | 9.38% |
| 2020 Q4 | 139.64 Million USD | 14.94% |
| 2020 Q1 | 76.29 Million USD | -65.58% |
| 2019 Q2 | 234.39 Million USD | 57.33% |
| 2019 Q1 | 148.98 Million USD | -8.53% |
| 2019 FY | 221.62 Million USD | 36.07% |
| 2019 Q3 | 223.71 Million USD | -4.56% |
| 2019 Q4 | 221.62 Million USD | -0.94% |
| 2018 FY | 162.87 Million USD | -14.69% |
| 2018 Q1 | 182.45 Million USD | -4.44% |
| 2018 Q2 | 176.58 Million USD | -3.22% |
| 2018 Q3 | 160.1 Million USD | -9.34% |
| 2018 Q4 | 162.87 Million USD | 1.73% |
| 2017 Q3 | 172.56 Million USD | -8.61% |
| 2017 FY | 190.93 Million USD | -13.62% |
| 2017 Q4 | 190.93 Million USD | 10.64% |
| 2017 Q2 | 188.82 Million USD | -11.76% |
| 2017 Q1 | 213.99 Million USD | -3.19% |
| 2016 Q3 | 202.76 Million USD | -4.68% |
| 2016 Q4 | 221.03 Million USD | 9.01% |
| 2016 Q1 | 224.66 Million USD | -1.72% |
| 2016 FY | 221.03 Million USD | -3.31% |
| 2016 Q2 | 212.73 Million USD | -5.31% |
| 2015 FY | 228.6 Million USD | -12.84% |
| 2015 Q4 | 228.6 Million USD | -4.5% |
| 2015 Q3 | 239.38 Million USD | -6.4% |
| 2015 Q2 | 255.76 Million USD | -0.47% |
| 2015 Q1 | 256.96 Million USD | -2.02% |
| 2014 Q2 | 265.76 Million USD | -2.55% |
| 2014 FY | 262.26 Million USD | -1.05% |
| 2014 Q3 | 254.48 Million USD | -4.24% |
| 2014 Q4 | 262.26 Million USD | 3.06% |
| 2014 Q1 | 272.7 Million USD | 2.89% |
| 2013 FY | 265.05 Million USD | 31.42% |
| 2013 Q4 | 265.05 Million USD | -1.51% |
| 2013 Q2 | 252.25 Million USD | 30.38% |
| 2013 Q1 | 193.48 Million USD | -4.07% |
| 2013 Q3 | 269.11 Million USD | 6.68% |
| 2012 Q1 | 30.3 Million USD | -4.69% |
| 2012 Q2 | 32.74 Million USD | 8.04% |
| 2012 Q3 | 35.24 Million USD | 7.63% |
| 2012 Q4 | 201.68 Million USD | 472.25% |
| 2012 FY | 201.68 Million USD | 534.27% |
| 2011 Q3 | 27.82 Million USD | 4.88% |
| 2011 Q1 | 24.91 Million USD | -23.51% |
| 2011 FY | 31.79 Million USD | -2.39% |
| 2011 Q4 | 31.79 Million USD | 14.28% |
| 2011 Q2 | 26.53 Million USD | 6.48% |
| 2010 Q3 | 25.38 Million USD | -5.61% |
| 2010 Q4 | 32.57 Million USD | 28.33% |
| 2010 FY | 32.57 Million USD | -10.77% |
| 2010 Q2 | 26.89 Million USD | -19.12% |
| 2010 Q1 | 33.25 Million USD | -8.92% |
| 2009 Q3 | 32.69 Million USD | 11.15% |
| 2009 Q4 | 36.5 Million USD | 11.67% |
| 2009 FY | 36.5 Million USD | -31.16% |
| 2009 Q2 | 29.41 Million USD | -18.35% |
| 2009 Q1 | 36.02 Million USD | -32.08% |
| 2008 Q2 | 46.87 Million USD | 4.92% |
| 2008 Q4 | 53.03 Million USD | 22.23% |
| 2008 Q3 | 43.38 Million USD | -7.43% |
| 2008 FY | 53.03 Million USD | 12.07% |
| 2008 Q1 | 44.67 Million USD | -5.6% |
| 2007 Q1 | 14.75 Million USD | 8.8% |
| 2007 Q4 | 47.32 Million USD | 2.84% |
| 2007 Q3 | 46.01 Million USD | 157.85% |
| 2007 Q2 | 17.84 Million USD | 20.94% |
| 2007 FY | 47.32 Million USD | 248.94% |
| 2006 Q4 | 13.56 Million USD | 5.19% |
| 2006 Q2 | 9.95 Million USD | 6.79% |
| 2006 Q1 | 9.31 Million USD | -11.79% |
| 2006 FY | 13.56 Million USD | 28.4% |
| 2006 Q3 | 12.89 Million USD | 29.58% |
| 2005 Q3 | 8.59 Million USD | 1.0% |
| 2005 Q1 | 7.89 Million USD | -36.79% |
| 2005 Q2 | 8.51 Million USD | 7.8% |
| 2005 FY | 10.56 Million USD | -15.46% |
| 2005 Q4 | 10.56 Million USD | 22.84% |
| 2004 Q4 | 12.49 Million USD | -50.72% |
| 2004 Q3 | 25.35 Million USD | 0.0% |
| 2004 FY | 12.49 Million USD | -51.13% |
| 2003 FY | 25.56 Million USD | 22.09% |
| 2003 Q4 | 25.56 Million USD | 0.0% |
| 2002 FY | 20.94 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 126.59 Million USD | 11.465% |
| AtriCure, Inc. | 147.76 Million USD | 24.146% |
| Avinger, Inc. | 19.97 Million USD | -461.211% |
| Azenta, Inc. | 351.22 Million USD | 68.087% |
| BioLife Solutions, Inc. | 75.05 Million USD | -49.345% |
| The Cooper Companies, Inc. | 4.1 Billion USD | 97.271% |
| Daxor Corporation | 858.75 Thousand USD | -12951.989% |
| Ekso Bionics Holdings, Inc. | 16.31 Million USD | -587.132% |
| Femasys Inc. | 9.4 Million USD | -1091.983% |
| GlucoTrack, Inc. | 1.7 Million USD | -6462.354% |
| Harvard Bioscience, Inc. | 64.29 Million USD | -74.337% |
| Hologic, Inc. | 4.02 Billion USD | 97.216% |
| ICU Medical, Inc. | 2.25 Billion USD | 95.03% |
| Intuitive Surgical, Inc. | 2.04 Billion USD | 94.517% |
| KORU Medical Systems, Inc. | 8.1 Million USD | -1282.536% |
| LeMaitre Vascular, Inc. | 48.87 Million USD | -129.316% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -16884.223% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -16884.223% |
| Masimo Corporation | 1.67 Billion USD | 93.315% |
| Microbot Medical Inc. | 3.82 Million USD | -2829.561% |
| Meihua International Medical Technologies Co., Ltd. | 25.07 Million USD | -346.955% |
| Merit Medical Systems, Inc. | 1.12 Billion USD | 90.021% |
| Nephros, Inc. | 3.5 Million USD | -3099.686% |
| NovoCure Limited | 783.63 Million USD | 85.697% |
| NEXGEL, Inc. | 4.78 Million USD | -2240.468% |
| NEXGEL, Inc. | 4.78 Million USD | -2240.468% |
| Singular Genomics Systems, Inc. | 86.46 Million USD | -29.636% |
| OraSure Technologies, Inc. | 52.17 Million USD | -114.829% |
| Pro-Dex, Inc. | 23.34 Million USD | -380.165% |
| Pulse Biosciences, Inc. | 16.44 Million USD | -581.616% |
| Predictive Oncology Inc. | 6.14 Million USD | -1723.864% |
| Precision Optics Corporation, Inc. | 6.84 Million USD | -1537.524% |
| QuidelOrtho Corporation | 3.55 Billion USD | 96.849% |
| Repligen Corporation | 853.2 Million USD | 86.863% |
| Sanara MedTech Inc. | 29.28 Million USD | -282.763% |
| STAAR Surgical Company | 102.73 Million USD | -9.098% |
| Sharps Technology, Inc. | 3.85 Million USD | -2807.536% |
| Utah Medical Products, Inc. | 7.14 Million USD | -1468.719% |
| DENTSPLY SIRONA Inc. | 4.07 Billion USD | 97.25% |
| Jin Medical International Ltd. | 8.92 Million USD | -1155.947% |